Immuno-oncology company with the BICSTA multispecific antibody and STARKINE cytokine platforms
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Series C MustBio raised KRW 35 billion (~$24.5M) in Series C funding to accelerate its next-generation immuno-oncology therapies. | $24.5M |
Data is community-curated and may be incomplete.